TARS as reported
Tarsus Pharmaceuticals, Inc. reported $606M of revenue over the trailing twelve months, +105% on the year before. 9 reported series are charted on this page, each one as filed.
$606M
Revenue, trailing twelve months · to Q2 2026 · +105% against the twelve months before
- Net Income
- −$46M
Net Income · −49% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $56M
Free Cash Flow · −168% year on year · trailing twelve months to Q2 2026
- Op Margin
- −8.2%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $606M | +105% | Q2 2026 |
| Net Income | −$46M | −49% | Q2 2026 |
| EPS | −$1.08 | −53% | Q2 2026 |
| Op Margin | −8.2% | n/a | Q2 2026 |
| Net Margin | −7.8% | n/a | Q2 2026 |
| ROE | −18% | n/a | Q2 2026 |
| ROA | −11% | n/a | Q2 2026 |
| ROIC | 688% | n/a | Q2 2026 |
| Free Cash Flow | $56M | −168% | Q2 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Tarsus Pharmaceuticals, Inc. (TARS) - Revenue & ProfitRevenue & ProfitTarsus Pharmaceuticals, Inc. (TARS)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com